Blood Thinner Drug Effient May Increase Cancer and Bleeding Risks

Effient (prasugrel), a blood thinning medication which competes with Plavix to prevent heart attacks and strokes, may have greater risks than previously thought. According to new studies, Effient patients have greater bleeding risks and increased instances of colon, lung and prostate cancer.

What Is Effient?

Effient (prasugrel) is a blood thinning medication that directly competes with Bristol Myers Squibb / Sanofi-Aventis Corporation's Plavix. Jointly marketed by Eli Lilly and Japanese pharmaceutical company Daiichi Sankyo, Effient was approved by the U.S. Food & Drug Association in July of 2009 to reduce the rate of heart attacks and strokes. However, recent studies show that Effient carries greater risks of injury and death than previously thought.

Studies Show Increased Effient Cancer Rates

Two articles recently published in the Archives of Internal Medicine reported that studies have cited increased counts of multiple types of solid tumors (such as colon, lung and prostate) in Effient patients. In fact, a clinical trial known as TRITON-TIMI 38, funded by Daiichi Sankyo and Eli Lilly themselves, analyzed 13,608 Effient and Plavix users over a 15 month time period. The results showed 92 new solid cancers in Effient patients as compared with 64 in Plavix patients.

In addition, the FDA performed its own analysis of cancer events and presented its findings to the Cardiovascular and Renal Drugs Advisory Committee. The FDA's analysis also showed that there was an increase in multiple types of solid cancers in Effient users.

Effient Side Effects

In addition to increased risks of multiple types of cancers, previous studies have shown that Effient side effects also include a significantly greater risk of bleeding events. In fact, the FDA requires the manufacturers to include a black box warning label which states that Effient “can cause significant, sometimes fatal, bleeding.” These Effient side effects are likely to result in Effient injury lawsuits in the very near future.

Effient Injury Lawsuits

Effient injury lawyers say that the manufacturers' lack of proper testing and failure to warn consumers about the increased risk of Effient injuries will likely result in Effient injury lawsuits – especially after a leading UCLA cardiologist reported that there are sufficient credible concerns about the drug and that additional research is needed and another doctor at John Hopkins stated that Effient may actually promote cancer growth by inhibiting the body's natural defenses against tumors.

If you've been injured due to Effient, contact an Effient injury attorney to discuss your situation, evaluate your options and determine whether you might be entitled to compensation for your injuries.